Archives
- 2018-07
- 2018-10
- 2018-11
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
-
br En las p ginas de
2019-05-24
En las páginas de La esquina de los ojos rojos, jóvenes “pránganas” escapando MRS 2578 Supplier toda velocidad sobre una motoneta, una vez cometido un asesinato, huyen a toda costa de una realidad vengativa, de los límites de un vacío personal, ético y de las cerradas posibilidades de esa asfixia
-
Con esto no se pretende se alar que en
2019-05-24
Con esto no se pretende señalar que en el terreno educativo no existan mentes lúcidas o que sus actores se comporten con una meridiana ingenuidad. Solamente queremos advertir que la constante necesidad de mejorar la educación y de aggiornar sus procesos 4-ap la dinámica cambiante de la sociedad, hac
-
The patient was consented to treatment on clinical trial
2019-05-23
The patient was consented to treatment on clinical trial NCT02527447 and received treatment with salvage chemotherapy of mitoxantrone 12mg/m2/day IV on days 1–3, etoposide 200mg/m2/day continuous IV infusion (CIV) on days 8–10, and cytarabine 500mg/m2/day CIV on days 1–3 and 8–10 (EMA). Infectious p
-
Programmed death ligand PD L expression is a characteristic
2019-05-23
Programmed death ligand 1 (PD-L1) expression is a characteristic feature of EBV-associated malignancies. Research has shown that an increase of PD-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma. Preliminary data from a phase Ib study, KEYNOTE-028, showed
-
CT analysis of tumour bearing bones
2019-05-23
μCT analysis of tumour bearing bones showed significantly increased bone density in animals receiving zoledronic acid, alone or in combination with doxorubicin, compared to PBS control. Our results confirmed that a single dose of zoledronic SB203580 caused sustained bone effects throughout the expe
-
A facility survey from reported that only of primary
2019-05-23
A facility survey from 2003 reported that 2-deoxy-d-glucose only 15% of primary health centres provided abortion services. Another study from Rajasthan state revealed that nine districts included 83% of all facilities whereas the remaining 22 districts included only 17%. Within districts too, abort
-
The other uncommon types of idiopathic VT such as
2019-05-23
The other uncommon types of idiopathic VT such as non-reentrant focal Purkinje VT, papillary muscle VT, and mitral/tricuspid annular VT may also present as incessant or repetitive forms of monomorphic VT. Importantly, an incessant nature of the VTs can secondarily decrease the global (not segmental)
-
MADIT trial enrolled adult patients with
2019-05-23
MADIT trial enrolled 196 adult patients with prior myocardial infarction more than 3 weeks (Q wave or elevated cardiac enzyme), with non-sustained ventricular tachycardia (a run of 3–30 of ventricular ectopic beats with a rate more than 120 beats per minute), with left ventricular ejection fraction
-
DIG-11-dUTP br Discussion Zoledronic acid has been approved
2019-05-23
Discussion Zoledronic DIG-11-dUTP has been approved for prevention and treatment of osteoporosis and glucocorticoids-induced osteoporosis, treatment of Paget\'s disease, hypercalcemia, multiple myeloma and bone metastasis. In the particular case of breast cancer, it is recommended as a monthly a
-
Octreotide acetate At least genes are associated with famili
2019-05-23
At least 15 genes are associated with familial LQTS, with 3 of these genes accounting for 70–75% of cases [5]. Despite advances in the understanding of the molecular basis of LQTS, challenges remain in making the clinical diagnosis. Importantly, between 10–40% of gene carriers have normal QT interva
-
In an earlier study we used a questionnaire to assess
2019-05-23
In an earlier study, we used a questionnaire to assess musculoskeletal pain in patients with CML who had achieved DMR (MR4.0) and discontinued TKI treatment, including IM, nilotinib, and dasatinib [5]. Nine out of the 27 patients surveyed developed musculoskeletal pain after discontinuing TKIs. In t
-
For most health care professionals
2019-05-23
For most health-care professionals, infectious-disease modelling is something of a black box. One can see the input assumptions (ie, what goes in) and the outputs (ie, what comes out), but what happens in between seems close to magic. Given their complexity, to understand any one of the models used
-
br Case A year old man was referred for
2019-05-22
Case A 45-year-old man was referred for the management of sudden-onset tachycardia. He had experienced 3 episodes of palpitation attacks, lasting for a couple of hours each, during the last 6 months. A regular, wide QRS complex tachycardia (WCT) at 150beats/min with a prominent retrograde P wave
-
The review Bile acid receptor link nutrient sensing
2019-05-22
The review “Bile HZ-1157 receptor link nutrient sensing to metabolic regulation” by Li and Li is focused on bile acid receptors in the regulation of hepatic glucose and lipid metabolism and inflammation. Cholestasis and NAFLD are inflammatory liver diseases. Triglycerides are non-toxic, but accumul
-
will be remembered as an exceptional year in
2019-05-22
2013 will be remembered as an exceptional year in shaping our strategy to control HIV/AIDS. Indeed, a few weeks after the 30th anniversary of the discovery of the virus, a decisive step was made in deciding how to use antiretroviral therapy (ART) for treatment and prevention worldwide. New WHO publi
15187 records 971/1013 page Previous Next First page 上5页 971972973974975 下5页 Last page